Oncology

Latest News

eye on pharma banner
Eye on Pharma: FDA, EMA Accept Biosimilar Applications; Biosimilar Trials Begin

March 9th 2023

The FDA and the European Medicines Agency (EMA) accepted applications for a trastuzumab biosimilar and an ustekinumab biosimilar, respectively, and Altos Biologics completed patient enrollment for a phase 3 trial assessing an aflibercept biosimilar.

man administering medicines with autoinjector pen | Image credit: RFBSIP - stock.adobe.com.
FDA Approves Autoinjector Version of Neulasta Biosimilar

March 6th 2023

woman receiving subcutaneous injection by a doctor
Review: 15 Years of Real-world Data Demonstrates Safety of Epoetin Alfa Biosimilar HX575

March 4th 2023

doctor talking to older woman patients receiving chemotherapy
Sintilimab Plus Bevacizumab Biosimilar Therapy Associated With Better Outcomes, Higher Costs Than Lenvatinib

February 25th 2023

Biosimilar Business Recap: New Ustekinumab Partnership; Similis Bio Biosimilar Programs; Celltrion Japan Launch
Biosimilar Business Recap: New Ustekinumab Partnership; Similis Bio Biosimilar Programs; Celltrion Japan Launch

February 23rd 2023

Video Series
Video Interviews
Podcasts
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner

More News

© 2023 MJH Life Sciences

All rights reserved.